This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sistare, F. D. Articles by DeGeorge, J. Search for Related Content PubMed PubMed Citation Articles by Sistare, F. D. Articles by DeGeorge, J. Social Bookmarking                         What's this?

Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals—Practical Pointers, Mechanistic Clues, and New Questions

Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA

Karol L. Thompson

Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA

Ronald Honchel

Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA

Joseph DeGeorge

Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, Maryland, USA

Transgenic mouse strains with genetic alterations known to play a role in the multistage process of carcinogenesis are being used increasingly as models for evaluating the human carcinogenic potential of chemicals and Pharmaceuticals. The Tg.AC transgenic mouse is one of the strains currently being used in such alternative short-term carcinogenicity testing protocols. This review is focused on recent data from studies designed to evaluate this model's ability to discriminate carcinogens from noncarcinogens. Details relating to protocol design that can significantly impact study outcome are described. Data relating to mechanisms of chemical tumor induction in the Tg.AC model are reviewed, and questions have been formulated to encourage research to further guide appropriate future applications of this model.

Key Words: Alternative Bioassay • Carcinogens • Skin Carcinogenesis • Tumor Promotion • Tg.AC Transgenic Mouse • v-Ha-ras Gene

International Journal of Toxicology, Vol. 21, No. 1, 65-79 (2002)
DOI: 10.1080/10915810252826028


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Lynch, J. Svoboda, S. Putta, H. E. J. Hofland, W. H. Chern, and L. A. Hansen Mouse Skin Models for Carcinogenic Hazard Identification: Utilities and Challenges Toxicol Pathol, December 1, 2007; 35(7): 853 - 864. [Abstract] [Full Text] [PDF]

				J. Fuhrman, L. Shafer, S. Repertinger, T. Chan, and L. A. Hansen Mechanisms of SEPA 0009-Induced Tumorigenesis in v-rasHa Transgenic Tg.AC Mice Toxicol Pathol, October 1, 2005; 33(6): 623 - 630. [Abstract] [Full Text] [PDF]

				K. L. Thompson and F. D. Sistare Selection of Drugs to Test the Specificity of the Tg.AC Assay by Screening for Induction of the gadd153 Promoter in Vitro Toxicol. Sci., August 1, 2003; 74(2): 260 - 270. [Abstract] [Full Text] [PDF]

				K. L. Thompson, B. A. Rosenzweig, J. L. Weaver, J. Zhang, K. K. Lin, and F. D. Sistare Evaluation of the Tg.AC Assay: Specificity Testing with Three Noncarcinogenic Pharmaceuticals that Induce Selected Stress Gene Promoters in Vitro and the Inhibitory Effects of Solvent Components Toxicol. Sci., August 1, 2003; 74(2): 271 - 278. [Abstract] [Full Text] [PDF]